U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
NORTH CHICAGO, Ailing., Jan. 14, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) in the present day introduced the U.S. Meals and Drug ...
